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57 ABSTRACT 
An optical probe is disclosed which is Suitable for rapidly 
measuring Raman spectra in Vivo. The probe is designed to 
minimize interfering Raman and fluorescence Signals gen 
erated within the probe itself. In addition, the probe design 
is compact, making it particularly Suited for use in confined 
SpaceS Such as body cavities. In one embodiment, the probe 
is employed to detect tissue abnormalities Such as cervical 
cancers and precancers. 
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SPECTROSCOPIC PROBE FOR IN VIVO 
MEASUREMENT OF RAMAN SIGNALS 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The invention relates to a device for detecting Raman 
Spectra from tissue Samples in Vivo. In particular, the probe 
is designed to emit electromagnetic radiation in the near-IR 
range, which will induce Raman emission spectra from 
tissue Samples in a patient. These tissues may be Suspected 
cancers or precancers, and their Raman emission Spectra 
permit an estimation of their relative abnormality. 
2. Related Art 
Cervical cancer is the Second most common malignancy 
among women worldwide. In 1995, it was estimated that 
4,800 deaths will occur in the United States alone from this 
disease and 15,800 new cases of invasive cervical cancer 
will be diagnosed (1). Although early detection of cervical 
precancer has played a central role in reducing the mortality 
associated with this disease over the last 50 years (2), the 
incidence of pre-invasive Squamous carcinoma of the cervix 
has risen dramatically, especially among women under the 
age of 35 (3). Existing Screening and detection techniques, 
the Pap Smear and colposcopy, have Several deficiencies that 
prevent efficient management of an otherwise controllable 
disease. The primary Screening tool is the Pap Smear, which 
has a high false negative error rate of 15-40% due to 
Sampling and reading errors (4). Colposcopy, which usually 
follows an abnormal Pap Smear, requires extensive training 
and its accuracy is variable and limited even in the hands of 
expert practitioners (5). The mortality of cervical cancer 
among women under 50 years increased by 3% between 
1986 and 1990, and this trend may continue unless further 
improvements are made in current detection techniques (6). 
Recently, fluorescence, infrared absorption and Raman 
Spectroscopes have been proposed for cancer and precancer 
Screening and diagnosis (7-13). Many groups have Success 
fully demonstrated the potential of spectroscopic techniques 
to improve diagnosis in various organ Systems (7–22). 
Intrinsic tissue fluorescence has been used to differentiate 
normal and abnormal tissues in the human breast and lung 
(7), bronchus (8) and gastrointestinal tract (9). Fluorescence 
Spectroscopy has been shown to be a promising technique 
for the clinical diagnosis of cervical precancer (10-12). 
To further improve the diagnostic capability of Spectros 
copy for detection of cervical precancers, Raman Spectros 
copy has been considered. In comparison with fluorescence, 
Raman Signals are weak and require Sensitive instrumenta 
tion for detection. However, only a limited number of 
biological molecules contribute to tissue fluorescence, most 
with broadband emission. Many more molecules are 
Raman-active, with fingerprint spectra providing molecular 
Specific information that can be applied to diagnose diseased 
tissue. As a result, in recent years, Several groups have 
Studied the potential of Raman spectroscopy for disease 
detection (13–21). Alfano et al. have used Fourier Transform 
Raman spectroScopy to detect gynecologic malignancies 
(16). Several groups have applied Raman spectroscopy to 
breast cancer detection (13, 18). Feld et al. have demon 
strated the use of NIR and UV resonance Raman spectros 
copy for identification of colon cancer and atherOSclerosis 
(17, 19, 20). 
Because most materials are Raman active, molecular 
Specific Study of Samples is possible. On the other hand, 
Since most molecules are Raman active, the materials used 











of Sample signal. Light typically is delivered using optical 
fibers made of Silica in a remote Sensing spectroscopic 
System. However, Silica has a strong Raman signal which 
overrides Sample Signal. Glass, which transmits the near 
infrared, has an intense fluorescence and Raman signal. 
However, UV grade Silica (or quartz) has a much lower 
fluorescence and Raman Signal and should preferably be 
used in a Raman System. The detected Silica Signal is 
generated in both the delivery and collection fibers used to 
measure tissue Raman spectra. A probe design should pre 
vent this unwanted Silica Signal from being detected, as well 
as allow maximum collection of tissue Raman Signal. 
Several different designs have been proposed for clinical 
acquisition of Raman spectra using fiber optic probes (24, 
25). In a breast tissue study, Frank et al. used two different 
fiber optic bundles: (i) a 6x1 fiber bundle accessible through 
a biopsy needle and (ii) an integrated 2x2 inch non-contact 
probe (DLT, Laramie, Wyo.), and tested it on breast tissue 
models and breast tissues in vitro (24). Fiber interference 
was found to be more Significant for cancer Samples with 
both probes due to reduced signal generation. 
Berger et al. used a compound parabolic concentrator 
(CPC) at the distal tip of a probe with multiple collection 
fibers to yield signals with Seven times more Signal as 
compared to using a fiber probe without the CPC (25). Fiber 
background was reduced by using a dichroic mirror and 
Separate excitation and collection fiber geometries. This 
probe design was used to acquire Raman spectra for trans 
cutaneous blood glucose measurements. Although the poten 
tial application of a similar probe for coronary artery mea 
Surements were made, no further publications on its 
Successful application have been found. 
Other Successful in vivo measurements have been in the 
eye (26), nail (27) and skin (28). Published reports of in vivo 
Raman applications have been confined to exposed tissue 
areas where fiber background could be circumvented using 
a macroscopic arrangement, e.g., DLT probe for breast 
tissues by Frank et al. (24) and CPC probe for transcutane 
ous measurements of blood analytes by Berger et al. (25). 
However, other organ Sites Such as the colon, cervix and oral 
cavity, require a more compact configuration and probe 
design. Thus, there clearly remains a need for improved 
optical probes capable of delivering near-IR electromagnetic 
radiation and detecting the resulting emission spectra in 
WVO. 
SUMMARY OF THE INVENTION 
It is an object, therefore, of the present invention to 
provide improved Raman spectroscopy probes for use in 
Vivo. It also is an object to provide a probe Suitable for use 
in a body cavity including, for example, the cervix. And it 
also is an object to provide a probe that has a minimal 
interfering Raman Signal. 
In Satisfying these objects, there is provided an optical 
probe for in Vivo examination comprising (a) a probe body 
having an optical opening at one end thereof, (b) an exci 
tation leg disposed in the probe body, the excitation leg 
having an optical axis; (c) a collection leg disposed in the 
probe body, the collection leg having an optical axis; and (d) 
a mirror in operable relation to the optical axis of the 
excitation leg. In one embodiment, the excitation and col 
lection legs are Separate. Advantageously, the excitation leg 
is comprised of optical excitation fibers and the collection 
leg is comprised of optical collection fibers. 
The excitation leg and the collection leg may be disposed 
longitudinally in Said probe body, with parallel optical axes. 
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The mirror can be used to establish an optical path from the 
optical axis of the excitation leg to the optical opening. The 
optical opening may comprise air or a material that has a 
relatively low Raman Signature, Such as quartz, Sapphire or 
transparent Teflon. 
In more Specific embodiments, the optical probe contains 
a focusing lens in the excitation leg. Also included in the 
excitation leg may be a filter, Such as an interference filter, 
in operable relation to the focusing lens. The interference 
filter may be a bandpass filter, having a 3–4 mm diameter 
and blocking light with OD grater than about 5. 
The optical probe may also contain a focusing lens in the 
collection leg, as well as a filter in operable relation to this 
focusing lens. The collection leg may advantageously 
employ a collimating lens in operable relation to the optical 
opening. An exemplary collimating lens would have a 
diameter of about 8 mm block light having an OD of greater 
than about 6. The collection leg filter may be a longpass filter 
or a notch filter. Advantageously, the notch filter is a 
holographic notch filter, having a diameter of about 8 mm. 
The number of collection fibers advantageously is 50, and 
the size of the collection fibers is 100 um. 
The mirror may be comprised of a polished gold wire. The 
polishing is advantageously conducted at a specific angle 
greater than the critical angle of quartz. Alternatively, the 
mirror is a parabolic mirror. 
The probe may include an anodized interior, a diameter of 
less than 20 mm. The probe body may be comprised of 
carbonized epoxy or aluminum. Additionally, the probe 
body may be encased in heat-shrink tubing. 
Another embodiment comprises an optical probe for in 
Vivo examination comprising an elongated probe body hav 
ing an optical window at one end thereof; an optical fiber 
disposed Substantially longitudinally in the probe body, the 
optical fiber having first and Second ends, an electromag 
netic Source coupler mounted on the probe body and coupled 
to the first end of the optical fiber; a first focusing lens 
disposed in the probe body and having an optical axis 
Substantially normal to the Second end of the optical fiber; an 
interference filter disposed in the probe body on the optical 
axis of the first focusing lens, a deflecting mirror disposed in 
the probe body on the optical axis of the first focusing lens, 
the interference filter being disposed between the first focus 
ing lens and the deflecting mirror; an optical fiber bundle 
disposed Substantially longitudinally in the probe body, the 
optical fiber bundle having first and Second ends, an elec 
tromagnetic receiver coupler mounted on the probe body, the 
electromagnetic receiver coupler being coupled to the first 
end of the optical fiber bundle; a collimating lens disposed 
in the probe body and having an optical axis Substantially 
normal to the second end of the optical fiber bundle; a 
holographic filter disposed in the probe body on the optical 
axis of the collimating lens and Substantially normal thereto; 
and a Second focusing lens disposed in the probe body and 
having an optical axis Substantially normal to the Second end 
of the optical fiber bundle, the holographic filter being 
disposed between the collimating lens and the Second focus 
ing lens, wherein the deflection mirror is angled with respect 
to the optical axis of the first focusing lens to establish an 
optical path from the optical axis of the first focusing lens 
that intersects with the optical axis of the Second focusing 
lens in a region proximate to and outside of the probe optical 
window. 
In still yet another embodiment, there is provided an 
apparatus for measuring Raman Spectra in Vivo comprising 











generator, a Raman spectrum detector; and a means for 
analyzing the Spectra in relation to the electromagnetic 
radiation. The electromagnetic radiation generator prefer 
ably is a laser. 
In still yet another embodiment, there is provided a 
method for collecting optical data from a Sample site in vivo 
comprising generating excitation electromagnetic energy, 
conducting the excitation energy longitudinally through a 
probe, concentrating the excitation energy during the exci 
tation energy conducting Step; filtering the excitation energy 
during the excitation energy conducting Step to eliminate all 
but a predetermined excitation wavelength from the excita 
tion energy; deflecting the excitation energy following the 
concentration and filtering Steps onto the Sample site; con 
ducting emission radiation resulting from the deflecting Step 
longitudinally through the probe, expanding the emission 
radiation during the emission radiation conducting Step; 
interference filtering the emission radiation during the emis 
Sion radiation conducting Step and after the expanding Step 
to eliminate the excitation wavelength from the emission 
radiation; concentrating the emission radiation during the 
emission radiation conducting Step and following the inter 
ference filtering Step; and collecting the emission radiation 
following the concentrating Step. In a particular 
embodiment, the probe comprises a window at an end 
thereof, the window having known fluorescence and Raman 
Signatures, an the method further comprising bring the 
window into proximity with the tissue site during the 
collection Step, and removing the known fluorescence and 
Raman Signatures from the collected emission radiation. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, Since various changes and modifi 
cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of the Specific 
embodiments presented herein. 
FIG. 1 is an illustration of the overlap in the imaging beam 
at the entrance slit of the spectrograph. (1) 100 mm slit; (3) 
200 mm imaging spot. 
FIG. 2 is a Schematic of the basic clinical Raman System. 
FIG. 3 is a schematic of a table top setup to test the source 
of fiber Signal. 
FIGS. 4A-D show Raman spectra of naphthalene with 
(FIG. 4A) no filters, (FIG. 4B) only a bandpass filter, (FIG. 
4C) only a holographic notch filter and (FIG. 4D) both 
bandpass and notch filters between the sample and fibers. S 
indicates Silica bands, N indicates naphthalene bands. 
FIGS. 5A-B are schematics of Raman probe designs 
using a dichroic mirror to filter the fiber interference using 
a wedged coated as a dichroic (FIG. 5A) or a flat dichroic 
placed at an angle (FIG. 5B). 
FIG. 6 is a schematic (to scale) of the final probe design 
Selected to be implemented as a clinical Raman probe. The 
probe was first built using this design. Only the inside face 
of the probe casing is illustrated. 
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FIG. 7 shows a Raman spectrum measured with the probe 
illustrated in FIG. 6 in air, 1 minute integration. 
FIG. 8 shows a Raman spectrum of the collection leg of 
the probe in FIG. 6. 
FIG. 9 shows a Raman spectrum of the excitation leg of 
the probe in FIG. 6. 
FIG. 10 ShowS Spectra of quartz and glass to indicate the 
advantage of using quartz instead of glass. 
FIG. 11 shows a spectrum obtained from the bandpass 
filter used in the probe (FIG. 6) using the in vitro Raman 
System. 
FIG. 12 is a modified schematic (to scale) of the final 
probe design that was rebuilt to solve the problems observed 
in the previous iteration. Only the inside face of the probe 
casing is illustrated. The total length of the probe is about 20 
cm, of which only a portion is illustrated. 
FIG. 13 shows a background spectrum measured with the 
reiterated probe in FIG. 12 in air (1 min. integration). 
FIG. 14 shows in vivo NIR Raman spectra from one 
normal and one abnormal Site in patient 2. Significant Silica 
peaks are observed at 626 and 818 cm which obscure any 
tissue peaks in this region. 
FIG. 15 shows in vivo NIR Raman spectra of the cervix 
before and after applying acetic acid on the Same Site in 
patient 3. 
FIG. 16 shows in vivo NIR Raman spectra from two 
different Sites in patient 3 to demonstrate intra-patient vari 
ability. 
FIG. 17 shows an experimental setup for the collection of 
near-IR Raman spectra. 
FIGS. 18A and 18B: FIG. 18A shows use of an algorithm 
employing a ratio of unnormalized intensities at 1656 cm 
and 1330 cm to separate SILS and non-SILs. 
FIG. 18B shows use of an algorithm employing a ratio of 
unnormalized intensities at 1656 cm and 1454 cm to 
separate high grade and low grade SILS. O - normal; 0 
- inflammation; D - metaplasia; A - low grade SIL, O - 
high grade SIL. 
FIG. 19 shows in vivo Raman spectra from one normal 
and one precancerous Site in one patient measured using a 
deep depletion CCD camera. 
DETAILED DESCRIPTION OF THE 
INVENTION 
A goal of the present inventors was to develop a probe 
capable of rapidly measuring Raman spectra in Vivo without 
Significant interference from materials used to construct the 
probe. Different probe designs were created to minimize 
fiber signal, leading to the development of a Raman probe 
which was Successful in measuring Raman spectra in Vivo. 
The advantages of the probe are its compact size, its 
relatively low Raman spectroscopic Signature and its accu 
racy in measurement of Raman spectra in a short period of 
time. These advantages are as a result of a unique design that 
involves a series of microlenses and microfilters. The fol 
lowing detailed description is provided. 
I. Raman Spectroscopy Probe for In vivo Use 
The present invention involves an optical probe, primarily 
for use in Raman spectroscopy, that can be employed to 
examine Sample Sites in Vivo. The invention comprises a 
Series of microlenses and microfilters which, in conjunction 
with an electromagnetic radiation Source and a detection 
System, permit measurement of Raman signals from tissues. 
Importantly, the probe is Small enough to pass inside body 











created cavity. In addition, the probe materials themselves 
have minimal Raman Signature, thereby avoiding Raman 
“noise” that would interfere with the Raman “signal” gen 
erated by the tissue. 
The probe employs two optical Systems: an excitation leg 
and a collection leg. The excitation leg delivers electromag 
netic radiation to a Sample site, while the collection leg 
collects Raman Spectral emissions and delivers them to a 
detection apparatus. An Overview of an exemplary System is 
show in FIG. 17. The laser light source is directed to a 
bandpass filter and then to a fiber that carries the electro 
magnetic radiation. Before reaching the Sample, Second 
bandpass filter is employed, and the resulting radiation 
wavelength is passed through a focusing lens to focus the 
radiation onto the Sample. 
Continuing with FIG. 17, the Raman emissions are passed 
through a collimating lens, a holographic notch filter, and a 
Second focusing lens. Thus processed, the optical emissions 
are delivered to a spectrograph and photographed with a 
CCD camera. The data are fed to a computer for further 
analysis. 
The microlenses and microfilters that comprise the probe, 
along with other probe components, are housed in a probe 
casing that protects the equipment from the Sample, and Vice 
Versa. The shape of the probe casing preferably is elongate, 
generally, to permit its location. Suitable materials for the 
probe include non-toxic plastics, Such as carbonized epoxy, 
or non-corrosive metals, Such as aluminum. More 
preferably, the probe is a hollow tube. Elements held within 
the probe may be fixed in place with glues, epoxies or resins. 
The materials should be kept out of the light pathway. 
At one end of the probe, optical conducting materials, 
Such as optical fibers, pass into the probe. This opening 
should be Sealed So that no light can pass into the interior of 
the probe. Similarly, the optical fibers are covered with light 
opaque materials, Such as black heat-shrink tubing. At the 
other end of the probe, the opening preferably is covered 
with a shield to seal the probe interior from the environment 
while permitting the excitation electromagnetic radiation to 
pass through, thereby exciting molecules in the Sample. The 
Shield also permits Raman spectra from the sample to pass 
through the Shield into the probe for collection purposes. 
Preferably, the shield material is selected to provide efficient 
transfer of electromagnetic radiation and reduced Raman 
interference. Suitable materials include quartz, Sapphire and 
transparent Teflon. Alternatively, a shield may be omitted in 
its entirety. 
For cervical applications, the Stiff Section of the probe 
must be at least 13.5 cm, preferably 20 cm, so that it can be 
advanced through the Speculum to the cervix. 
The microlenses serve to (i) direct and concentrate the 
excitation radiation onto the sample area, (ii) expand the 
emission radiation prior to interference filtering and (iii) 
concentrate the emission radiation prior to collection. Con 
centration is accomplished by focusing lenses and expansion 
is accomplished by collimating lenses. The microfilters 
serve to (i) eliminate all but the selected wavelength from 
the excitation beam and (ii) eliminate the excitation wave 
length from the emission spectrum. An alternative to filter 
the excitation wavelength prior to the Sample is the use of 
dielectrically coated fibers that have minimal reflectance. 
The elimination of the excitation wavelength may be 
achieved with a holographic notch filter. The combination of 
these features is particularly effective at achieving the 
advantages noted above. 
Another feature in the probe is the use of a mirror to direct 
the excitation beam onto the Sample Site. The mirror uses a 
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polished gold wire; the polishing is conducted So that the 
beam Strikes the normal to the quartz Shield at less than the 
critical angle of quartz to prevent total internal reflection. 
Optionally, a parabolic mirror may be employed for this 
purpose. 
FIG. 12 shows an exemplary probe configuration. Elec 
tromagnetic radiation from the radiation Source is delivered 
to the probe casing 1 and transmitted through a 200 um core 
excitation fiber 3. The electromagnetic radiation first passes 
through a focussing lens 5, and then through a bandpass 
filter 7. The filtered radiation then strikes a mirror 8 (angle= 
67 from normal) and is reflected through the probe window 
9 onto the Sample area. Emitted radiation passes back 
through the probe window 9 and through a collimating lens 
11 (f=11 mm; d=8 mm). Next the radiation passes through 
a holographic notch filter 15 (d=8 mm) and then through a 
Second focussing lens 17 (f=11 mm; d=8 mm). An anodized 
beam stop 13 is located at the notch filter to prevent any 
extraneous emission from bypassing the filter. The remain 
ing radiation is transmitted out of the probe via fifty 100 um 
core diameter collection fibers. The collection fibers are held 
by a support 19. This radiation is delivered to the detection 
apparatus. The total length of the probe is 20 cm. The width 
of the window is 8.5 mm. The total width of the probe is 20 
. 
The dimensions for the exemplary embodiment and the 
distances between elements can readily be derived from the 
size bar on FIG. 12. In general, it should be noted that the 
distance between the Sample and the collimating lens should 
be the focal length of the collimating lens. Similarly, the 
distance between the collection fibers and the Second focus 
sing lens is the focal length of the Second focussing lens. In 
addition, the distance between the first focussing lens and 
the excitation fiber is Such that the image of the excitation 
fiber is formed at the outer Surface of the shield. 
The 200 um core excitation fiber is available as Super 
guide UV thermocoat 220T from Fiberguide. The first 
focussing lens is available from CVI Lasers (d=3 mm; f=14 
mm). The bandpass filter is available as BP805-4, Omega. 
The collimating and Second focussing lenses are available 
from Republic Lenses. The holographic notch filter is avail 
able as HIPF-789-8 from Kaiser, Ann Arbor, Mich. The 100 
tum core diameter collection fibers are available as Super 
guide UV thermocoat 120T from Fiberguide. It should be 
noted, however, that there are Suitable, commercially avail 
able Substitutes for each of the mirror, fibers, filters and 
lenses described in this paragraph. 
Lasers generally are employed as the electromagnetic 
radiation Source. In accordance with the present invention. 
For example, a 40 mW GaAlAs diode laser (Diolite 800, 
LiCONix, Santa Clara, Calif.) can be used to excite samples 
at 789 nm through a 100-200 um core diameter glass optical 
fiber. Laser power may advantageously be maintained at 15 
mW (+1%). 
An exemplary detection System includes an imaging 
spectrograph (Holospec f1.8, Kaiser, Ann Arbor, Mich.) and 
a liquid nitrogen cooled CCD camera (LNCCD-1024 
EHRB, Princeton Instruments, Trenton, N.J.). The spec 
trograph may advantageously be used with a 300gr/mm 
grating, blazed at 500 nm, which yields a spectral resolution 
of 10 cm with an entrance slit of 100 um. Alternatively, 
one may employ a Series of bandpass filters and avalanche 
photodiodes to detect Selected emission frequencies. A com 
puter (Austin 486 75 Mhz, Austin, Tex.) is used for data 
processing. 
II. In Vivo Methods 
One use to which the probe of FIG. 12 may be applied 











Sample. Four basic steps are involved: (i) providing a tissue 
Sample; (ii) illuminating said sample with an electromag 
netic radiation wavelength from the near infrared to produce 
a Raman spectrum shifted from the illumination wavelength; 
(iii) detecting a plurality of emission frequencies of Said 
spectrum; and (iv) establishing from Said emission frequen 
cies a probability that Said Sample is abnormal. The illumi 
nation wavelength may be about 700-850 nm, and more 
specifically about 790 (+/-10) um. 
The establishing Step may comprise measuring Said emis 
Sion frequencies relative to the illuminating electromagnetic 
radiation wavelength. Relevant emission frequencies are 
advantageously shifted about 626, 818, 978, 1070, 1175, 
1246, 1330, 1454 and 1656 cm from an illumination 
wavelength of 789 nm. For example, emission frequencies 
shifted about 1070 cm and about 1656 cm from the 
illumination wavelength distinguish precancers and non 
precancers. Emission frequencies shifted about 1330 and 
1656 cm from the illumination wavelength distinguish 
precancer and non-precancers. Emission frequencies shifted 
about 1454 and 1656 cm from the illumination wavelength 
distinguish low grade precancerous and high grade precan 
CCOS. 
Part of this method relies on a mathematical model for 
predicting abnormality in a tissue Sample. This model is 
derived from a Statistical analysis of Samples and involves 
forming a Set of principal components from preprocessed 
data, the principal components being defined as providing 
Statistically significant differences between normal tissue 
and various forms of abnormal tissue. Further, the principal 
components are Subjected to logistic discrimination to 
develop the relevant mathematical model. 
In another embodiment, the method of detecting tissue 
abnormality in a tissue sample focuses on determining the 
Raman Signatures of particular molecules, for example, 
collagen, phospholipids and glucose-1-phosphate. This 
method is fully described in a U.S. patent application, filed 
on Jun. 19, 1996, entitled “NEAR-INFRARED RAMAN 
SPECTROSCOPY FOR IN VITRO AND IN VIVO 
DETECTION OF CERVICAL PRECANCERS,” which is 
incorporated herein by reference in its entirety. 
In a clinical Setting, the Raman spectroScopy System of 
the present invention is applied as follows: 
The instrument should be turned on and calibrated for 
Spectral responsivity and intensity. 
Acetic acid is applied to the cervix. Areas to be inspected 
are identified. 
The probe is directed to each area on the cervix to be 
inspected. Multiple placements of the probe may be neces 
Sary. Use of a visible guiding beam will ensure that the 
active area of the probe is aligned with the intended area of 
the Sample. One of the optical fibers in the collecting leg 
may be coupled to a laser and used to provide the Visible 
guiding beam. 
The cervix is illuminated with excitation wavelengths at 
about 789 nm. The probe will detect the resulting spectrum, 
which will contain a combination of tissue fluorescence and 
Raman Signals. 
Data from each spatial location assessed will be processed 
to remove the fluorescence information, improve the Signal 
to noise ratio, resulting in the Raman spectrum from each 
Site. Analysis Steps carried out in the instrument Software 
include: 
Data recorded from each spatial location on the cervix are 
pre-processed in two ways, fluorescence Subtraction and 
convolution. 
Fluorescence Subtraction is carried out by fitting the tissue 
spectrum to a low order (3rd-5th) polynomial, which cap 
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tures the Slowly, Spectrally-varying fluorescence 
information, but not the narrow band Raman information. 
The best fit polynomial is then subtracted from the tissue 
Spectrum, yielding the Raman spectrum. 
The resulting Raman Spectrum is then convolved with a 
10 
Raman Signal generated by rhodamine 6G was back 
calculated, given that 6.4 electrons/second were detected by 
the CCD camera. In this calculation, the detached signal was 
divided by the fractional Signal lost at each Signal interface 
Gaussian function whose width matches the Spectral reso- in the System to obtain the amount of Raman Signal collected 
lution of the Spectrometer. This improves the Signal to noise by the collimating lens in the in vitro setup. Table 1 shows 
ratio of the Raman spectrum. these SIN calculations for each Step along with the equations 
The processed data vector from each site (DN) is then used. A Lambertian distribution (29) was used to calculate 
used to determine the condition of the measured tissue. This to the Raman signal generated by rhodamine 6G for a given 
can be accomplished in several ways. In one method, the Spot size which accounts for the angular distribution of 
processed data vector is multiplied by the reduced e1gen- Raman Scattering. 
vector matrix Stored in memory (Cn"). Cn' contains only 
those eigenvectors which displayed Statistically significant Table 1 shows that 93% of the light was lost at the 
differences for Sample to be classified. 15 imaging end due to mismatch in the numerical aperture 
The Fisher Score is calculated for each Sample using (NA) between the collection lenses (which performed 1:1 
Fisher's discriminant analysis. In this calculation, the mean imaging) and the spectrograph. The mismatch in Spot to slit 
values and standard deviations of the PC scores for normal Size at the entrance of the Spectrograph accounted for an 
Squamous epithelium and SILS Stored in memory are used. additional 37% loss. Note that a 100 um slit was used at the 
Using this algorithm, Sites with a Fisher Score of being entrance of the Spectrograph with the Spot size at the Sample 
normal Squamous epithelium greater than a threshold value at 200 um in the in vitro system (FIG. 1). 
TABLE 1. 
Signal-to-noise calculation showing the light losses in the path of collection for different configurations. 
50(100 um) Probe 
in vitro units fibers Probe (QE & 
Variables Relationship setup (Initial Probe) Probe (QE) Power) 
Time Integration for tissue 900 sec 21 370 8O 1. 
Improvement Factor SnewSold 42.5 2.4 11.3 24.8 
Detected Signal of divide by time 6.4 e?sec 272.04 15.51 72.37 385.9 
rhodamine 6G 
loss factor product of all losses O.O342 2,044 1.23 5.72 30.53 
CCD quantum efficiency at 1656 cm (900 nm) O.15 O.15 O.15 O.7 O.7 
Transmittance of grating estimated O.8 O.8 O.8 O.8 O.8 
Reflectance of mirrors estimated O.997 O.997 0.997 O.997 O.997 
Area mismatch at slit lit area/image area FIG. 8.1 O636 1. 1. 1. 1. 
NA mismatch tan (a" SIN(NApe)) O.O26 O.99 O.99 O.99 O.99 
an-a-siNNAE), 
Transmittance of glass estimated O.98O1 O.98 O.98 O.98 O.98 
Fresnel Losses estimated 0.78 O.78 0.78 O.78 O.78 
Transmittance of filter estimated O.9 O.9 O.9 O.9 O.9 
Power measured 25 nW 25 15 15 8O 
Raman signal collected total signal/Lifactor 187.25 ph/sec/mW 133.08 12.644 12.644 12.644 
Area of collection pi* r - radius of fiber or lens 5.067 cm2 O.OO785 O.OO785 O.OO785 O.OO785 
Distance to sample D 3.3 cm O1 O.9 O.9 O.9 
Angle of collection from sample normal to fiber 75 degrees 7.83 33 33 33 
Lambertian factor D/(COS(angle)*pi) 8.304 I?sr 128.52 122.97 122.97 122.97 
Total signal generated product of Lifactor and signal 1554.89 ph/sec/sr/mW 1554.89 1554.89 1554.89 1554.89 
Stored in memory are classified as non-SIL. Remaining Sites 
are classified as SIL. 
Other methods of analysis would include using intensites 
at 1070 cm and 1656 cm to determine whether a sample 
is precancerous, using intensities at 1330 cm and 1656 
cm to determine whether a sample is precancerous, and 
using intensities at 1454 cm and 1656 cm to determine 
if a precancer is low grade or high grade. 
III. In Vitro Raman System 
To obtain tissue Raman Signal with acceptable signal to 
noise ratio (S/N), the Signal from cervical biopsies has been 
integrated for about 15 minutes using an earlier in Vitro 
Raman System. To construct a feasible clinical System, the 
integration time needs to be Significantly reduced to the 
order of a few minutes. In order to determine the Sources of 
loSS in the in vitro System, Signal to noise calculations were 





To account for the NA mismatch, a new spectrograph 
(Kaiser Holospec, Ann Arbor, Mich.) with an NA of 0.27 
(comparable to that of a typical fiber) was used in the clinical 
Raman System. To maintain the Spectral resolution of the 
system at 10 cm, a 100 um slit needs to be used in the 
clinical system as well. Hence, 100 um core fibers were 
Selected for the probe collection bundle to minimize Signal 
loSS due to this mismatch. The power of the excitation light 
could be potentially increased to further improve the S/N 
and hence reduce the integration time. However, in consid 
eration of the ANSI safety standards, a higher power laser 
was decided against at that time. FIG. 2 shows the clinical 
Raman system developed as described above where the 
Same basic System except the probe used is maintained 
throughout these Studies. 
IV. In Vivo Probe Development 
Based on the S/N calculations, all in vivo probes were 
designed to have a single excitation fiber with a 200 um core 
diameter. Multiple 100 um core collection fibers were used. 
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The collection fibers were aligned to form a line of fibers at 
the spectrograph. The height of CCD camera determines the 
number of fibers that can be imaged by the detector. The 
height of the CCD camera used in the Raman system is 6.7 
mm and hence a maximum of 50 collection fibers could be 
used. 
Initial Probe Design: The first fiber optic probe was 
designed to collect Raman spectra prior to knowledge of 
fiber Signal interference. This probe consisted of a central 
excitation fiber (200 um core diameter) surrounded by 50 
collection fibers (100 um core diameter) at the probe tip. The 
excitation fiber was coupled to the laser and the collection 
fibers were linearly aligned at the entrance Slit of the 
Spectrograph. The probe was tested with and without a 
quartz shield (1 mm thick) at the probe tip. Table 1 also 
shows S/N calculations performed to estimate the improve 
ment in Raman signal collection when fifty 100 um collec 
tion fibers, with 0.22 NA, are used. The power and spot size 
of illumination and collection used in the in vitro Studies 
were retained. The matching in NA as well as the Spot size 
at the entrance slit of the spectrograph were included. All 
other parameters were maintained as before. An improve 
ment factor of 43 was obtained thus reducing the integration 
time to 20 seconds for a S/N similar to in vitro Raman 
spectra (Table 1, column 5). However, tissue signal could 
not be detected using this probe. 
Subsequent Probe Designs: The interfering fiber signal is 
generated in the delivery fiber by the excitation light. In 
addition, Signal also is generated in the collection fibers by 
the elastically scattered light as well as the Fresnel reflected 
excitation light returning into the collection fiber(s). A 
feasible probe design should prevent unwanted Signal gen 
erated in the delivery fiber from illuminating the Sample as 
well as prevent elastically Scattered excitation light from 
entering the collection fibers and generating unwanted Sig 
nal. A bandpass filter could be placed after the excitation 
fiber allowing only the transmission of the excitation light 
and blocking the Raman Signal from the delivery fiber. A 
long pass filter which blocks the transmission of the Fresnel 
reflected excitation light, as well as the elastically Scattered 
light, from entering the collection fibers filter could be 
placed between the Sample and collection fibers, preventing 
the generation of fiber Signal from the probe. 
Naphthalene (which is highly elastically scattering) was 
used as a Standard to ascertain the primary Source of the fiber 
Signal observed. A table top experimental Setup was 
arranged to perform these tests (FIG. 3). The separate 
excitation and collection legs were placed at a Small angle 
relative to each other. The excitation beam was focused on 
the Sample. The collected Raman Scattering was collimated 
and then refused onto the imaging bundle of fibers (fifty 100 
Aim collection fibers). 
FIG. 4A-D shows the Raman spectra of naphthalene 
obtained with (A) no filters between the sample and the 
fibers, (B) only a bandpass filter between the sample and 
excitation fiber, (C) only a holographic notch filter between 
the sample and collection fibers and (D) both bandpass and 
notch filters between the Sample and fibers. A significant 
Silica Raman Signal is detected in FIG. 4A-C, indicating that 
Significant proportions of Silica Signal are generated in the 
excitation and collection fibers. FIG. 4D shows that filters 
are needed to block the fiber interference from both the 
excitation and collection fibers of the probe. 
Detectable tissue Raman Signal could be obtained using 
the table top Setup with 5 minute integration time. The next 
Sections described Several configurations of a fiber optic 











should be noted that the fiber probe is being designed to use 
on the human cervix and hence needs to be compact in 
configuration while collecting maximum tissue Raman Sig 
nal. 
Preliminary Design of Clinical Probe: The simplest 
design would require the face of the fibers in the probe to be 
coated with appropriate dielectric materials that accomplish 
the filtering of excitation electromagnetic radiation. It is 
possible to obtain optical fibers with anti-reflective coating 
at its tip. Using this approach, it is possible to coat the 
excitation fiber Such that it only transmits the excitation light 
at 790 um (+/-10 nm) and blocks the longer wavelengths. It 
also is possible to coat the collection fiberS Such that light at 
790 um is blocked while transmitting longer wavelengths. It 
was found that although this is feasible, it is extremely 
expensive. Moreover, the rise band of transmission of the 
coatings may be more gradual than acceptable for Raman 
measurements (a rise band of 25 nm is required while both 
coatings would have a 60 nm rise band to transmit or block 
only above 850 nm). A longpass or notch filter with band 
pass characteristics at its center could be placed at the tip of 
the fiber bundle to provide the same filtering effect as would 
coatings. 
FIG. 5 illustrates another design that could be easily 
implemented as a Raman probe. A dichroic mirror that 
reflects the excitation light at 790 nm and transmits light at 
longer wavelengths, could be used at the probe tip to provide 
the filtering required to block fiber interference. This mirror 
may be optically flat that is placed at a 45° angle or a wedge 
with a dichroic coating. This probe consists of a side firing 
excitation fiber at 790 nm which is reflected by the dichroic 
mirror. 
The Raman signal at longer wavelengths is transmitted by 
the mirror on to the 50 collection fibers packed together. A 
dichroic mirror as Small as 3 mm is available commercially. 
Hence, it is feasible to build such a probe. Presently, optimal 
dichroic mirrors are usually only about 90% efficient, 
however, which may not provide Sufficient blocking, in and 
of itself, of the excitation fiber Raman or the excitation light 
into the collection fibers. 
Penultimate Probe Design: FIG. 6 shows a transverse 
Section of the probe design that was chosen to be imple 
mented as a Raman probe. This probe design is based on the 
optrode by Myrick et al. (30) and represents a miniaturiza 
tion of the table top setup described in FIG. 3 with further 
improvements for the in Vivo application. Rather than plac 
ing the excitation leg at an angle, a mirror is placed in the 
excitation path to deflect the beam onto the Sample. This 
probe was designed using the Smallest available physical 
dimensions of both the bandpass and holographic notch 
filters. However, filters are, in general, most efficient when 
light is normally incident, hence the excitation and collec 
tion legs were initially designed to collimate the light in the 
probe. This requirement is more rigid for the holographic 
notch filter. The excitation light is delivered by a 200 um 
core fiber coupled to a 0.18P graded-index (GRIN) lens 
which approximately collimates the beam. A 3 mm round 
bandpass filter was placed after the GRIN lens to transmit 
the excitation light and block the longer wavelengths. This 
deflecting mirror in the excitation leg of the probe can be a 
flat mirror that does not affect the excitation beam. A 
parabolic mirror also can be used Such that the beam is 
focused onto the Sample increasing the incident irradiance. 
The requirements for a parabolic mirror are very Specific in 
dimensions as well as in its focal length. Due to the 
unavailability of an appropriate parabolic mirror, a flat 
mirror was used. A gold wire was polished at an angle of 67 
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from the normal and glued in place Such that the deflected 
excitation and normal collection spots overlap. 
The Raman signal from the sample is collected by the first 
lens and collimated. An 8 mm round holographic notch filter 
blocks the excitation light with an OD of 6 and transmits at 
the longer wavelengths with an efficiency of 90%. A second 
lens focuses the beam onto the 50 tightly packed collection 
fibers. Although the external diameter of the notch filter is 8 
mm, the working area of the filter is only 4 mm in diameter. 
Hence the lenses were designed to yield a collimated beam 
that is less thin 4 mm in diameter while producing a 1:1 
image at the collection fibers. These fibers are arranged in a 
line at the detection end. One of the collection fibers was 
directed to form an additional leg to couple a helium neon 
laser through it, to provide an aiming beam during the 
placement of the probe on the sample. A quartz, Shield was 
used at the tip of the common end of the probe forming a 
barrier between the probe optics and the Sample. Quartz was 
Selected as the material of choice as its fluorescence and 
Raman Signal were known and any additional background 
signal from the probe could be identified. 
The first iteration of the probe, shown in FIG. 6, could not 
be used to measure tissue Raman spectra. FIG. 7 shows the 
background Subtracted Spectrum obtained for 1 minute inte 
gration using the system in FIG. 2 and the probe in FIG. 6 
held in air. A large fluorescence Signal is observed, in 
addition to Some Silica Raman Signal. Tests were performed 
to identify the source of the problem. 
Excitation light was directed into the collection end of the 
probe and the resultant Signal was measured by the detector 
(FIG. 8). FIG. 9 shows the signal detected when the light 
from the excitation leg of the probe is directly coupled into 
the spectrograph. FIGS. 8 and 9 show that fluorescence is 
generated in both legs of the probe. It was identified that 
glass lenses had been used in the collection leg which have 
a greater Signal than quartz. The excitation spot at the Sample 
was 2.3 mm in diameter, while only a 1 mm spot was imaged 
by the collection fibers. Due to the large excitation spot size, 
the mirror used to direct the beam onto the Sample was being 
overfilled resulting in multiple reflections of light as well as 
Signal from the glue which holds the mirror in place. 
In addition, the bandpass filter also shows a significant 
fluorescence signal (1131). The bandpass filter was deter 
mined to be made of absorption glass which generates 
fluorescence. When the probe is placed on a tissue sample, 
only the fluorescence Signal is detected from the probe. This 
inherent probe fluorescence results in a proportional shot 
noise which obscures any tissue Raman Signal present. It 
was necessary to eliminate a significant amount of this 
background fluorescence before any tissue Raman Signal can 
be detected. 
A new probe, which is the probe of FIG. 12, was con 
Structed using the same basic design described in FIG. 6 
with Several modifications. First, the glass lenses in the 
collection leg were replaced with quartz lenses. Second, the 
excitation beam was focused Such that the excitation and 
collection spots overlapped. Hence, the GRIN lens in the 
excitation leg was replaced with a 3 mm diameter quartz lens 
to yield a 900 um excitation spot. The excitation beam was 
verified to be incident within the dimensions of the mirror. 
Third, the inner Surfaces of the metal tubings used to house 
the probe optics were anodized to reduce the incidence of 
multiple reflections of light. Fourth, a new bandpass filter 
without absorption glass was used. Fifth, the existing quartz 
shield was replaced with a thinner one (0.5 mm instead of 1 
mm). Although the use of an anti-reflective coated quartz 
Shield was considered, it was not implemented due to 












FIG. 13 shows the signal obtained with the reiterated 
probe of FIG. 12 in air for 1 minute integration. Unlike the 
spectrum in FIG. 7, no fluorescence is observed. The peaks 
observed at 400, 626 and 818 cm are silica Raman peaks 
which arise from the quartz, Shield used as expected. The 
efficiency of this detection System results in a calculated 
reduction in time integration to about 80 seconds (Table 1, 
column 6). 
A CCD camera was tested using the Raman probe of FIG. 
12 and system described in FIG. 17. Raman spectra were 
acquired in Vivo from three patients using this CCD camera 
with two minute integration time. FIG. 19 shows the spectra 
obtained from a normal verSuS precancerous lesion from one 
of these patients. A back-illuminated chip is known to 
produce etaloning as a result of multiple reflections of the 
photons within the chip, which is observed as an interference 
pattern overriding the measured Spectrum detected by the 
camera. However, it is observed that the test camera displayS 
only a 3-4% etaloning which is not manifested in the 
observed Raman spectrum (FIG. 19). 
The tissue Raman spectra were analyzed only between 
600 and 1800 cm; the silica peak at 400 cm is not 
considered relevant for tissue Raman acquisition. The probe 
was tested on the buccal mucosa of a Volunteer and Raman 
signal with S/N slightly lower than that of in vitro tissue 
Raman Spectra was obtained. Five minutes time integration 
was required. This corresponds with the results displayed in 
Table 1, column 6, which calculates a time integration of 370 
Seconds (~6 min). 
V. Examples 
The following examples are included to demonstrate 
preferred embodiments of the present invention. It should be 
appreciated by those of Skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventors to function well in the practice 
of the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
Materials and Methods: Background interference from a 
probe was tested using Raman signals obtained from 
rhodamine 6G, naphthalene, potassium iodide and in air and 
compared to that obtained using the in vitro System shown 
in FIG. 17 with the bandpass filter placed after the excitation 
fiber. Spectra acquired from cervical biopsies in Vitro and 
from mouth in vivo were used to test the efficiency of the 
System for obtaining tissue Raman spectra. 
NIR Raman spectra of the cervix were successfully mea 
Sured in Vivo from 4 patients. Each patient underwent a 
complete exam which included a history, a Pap Smear and 
colposcopy of the cervix, Vagina and Vulva. In all except one 
patient, spectra were acquired from about two sites in each 
patient after colposcopic examination of the cervix. Biopsies 
were obtained only from abnormal sites analyzed by the 
probe and histology was performed. 
In vivo Raman spectra from the cervix were obtained 
using the same laser and detector as in FIG. 17. The new 
spectrograph and probe (FIG. 12) were used. The laser 
power at the tip of the probe was 15 mW with a spot size of 
900 um. All in vivo spectra were obtained with 5 minute 
time integration. The tissue Raman spectra were background 
Subtracted and calibrated for the wavelength dependence of 
the filters, Spectrograph, grating and detector. The calibrated 
Raman spectra were then noise-Smoothed using a Fourier 
filter as well as fluorescence-Subtracted using a high order 
polynomial fit (22). 
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Results: NIR Raman spectra of the cervix were measured 
in vivo from four patients. Of the four patients studied, one 
patient (Patient 2) had an abnormal lesion which was 
biopsied. The biopsy was histologically classified as a high 
grade Squamous intraepithelial lesion (SIL) with moderate 
Severity. All others were follow-up patients with a normal 
cervix. 
FIG. 14 shows the Raman spectra of a normal and SIL site 
investigated in patient 2. Examination of the Spectra 
between 900 and 1800 cm indicate that tissue peaks are 
observed at 934, 1066, 1147, 1175, 1204, 1252, 1321, 1343, 
1401, 1452, 1570 and 1659 cm. The peak at 936 cm is 
present with about equal intensity in both the normal and 
SIL Spectra of this patient. The intensity of the glucose 
phosphate peak at 1066 cm is greater in the SIL spectrum 
as compared to the normal in patient 2. The intensity of the 
1321 cm band is similar in the normal as well as the 
abnormal spectra in this patient. However, the unnormalized 
ratio of intensities at 1659 and 1321 cm is less than 1.9, 
classifying the Sample as a SIL using an in vitro algorithm, 
as shown in FIG. 18A. In addition, the unnormalized ratio of 
intensities at 1659 and 1452 cm, is less than 1, classifing 
the Sample as a high grade lesion using an in vitro algorithm 
in FIG. 18B which agrees with the histology. 
Two Raman spectra were obtained in patient 3 from the 
Same normal Site, one before applying acetic acid and one 
after applying acetic acid, a Standard procedure during 
colposcopy. Acetic acid causes abnormal areas to become 
white which enhances lesion Separation. To ascertain that 
application of acetic acid does not affect tissue Raman 
Spectra, pre-acetic acid and post-acetic acid spectra were 
compared (FIG. 15). 
A trace of the in vitro peak at 978 cm (not shown) in the 
pre-acetic spectra which is lost in spectra acquired post 
acetic acid. An increase in the intensity of the post-acetic 
acid peak at 1066 cm, attributed to glucose 1-phosphate is 
the primary spectral variation. The peak at 1147 (not shown) 
cm' has a lower intensity in the post-acetic acid spectrum. 
An additional peak at 1520 cm (not shown) is also 
observed in the post-acetic acid spectrum. However, this 
peak is not consistently observed in all post-acetic acid 
Raman Spectra obtained from normal Sites in other patients. 
To assess the intra-patient variability in cervical tissue 
Raman spectra acquired in Vivo, two different normal Sites 
were investigated in patient 4 (FIG. 16). Comparison of the 
Raman Spectra from the two Sites show Some variation in the 
intensity of Several peaks but the ratio of intensities between 
peaks remains the same. For example, the ratio of intensities 
at 1659 and 1452 cm is 0.72 in normal 1 and 0.77 in 
normal 2. In addition, the peak at 978 cm is present in 
normal 2 but is absent in normal 1. 
Discussion: The in vivo Raman spectra observed here 
appear Similar to in vitro Raman spectra obtained with a 
bandpass filter placed before the excitation fiber. Compari 
Son of the Raman peaks observed in cervical tissue Spectra 
acquired in Vivo and in Vitro Show Similar primary Raman 
peaks. A Raman peak at 934 cm' is observed in all in vivo 
spectra, but is not observed in vitro. On the other hand, in 
vitro Raman spectra showed a peak at 978 cm which is not 
consistently observed in vivo. The in vivo peak at 934 cm 
was previously reported by Liu et al. (31) in normal and 
“benign' Samples, “benign' including SILS. Comparison to 
the chromophore Spectra indicates that this peak may be due 
to the presence of glucose. Glycogen also has a peak at 940 
cm. The peak at 978 cm was earlier assigned to glucose 
1-phosphate. Glucose-1-phosphate is an intermediate prod 











dantly present in normal cervical epithelium. This may 
explain the presence of Signal arising from these compo 
nents and the variability in their presence. The amide bands 
at 1252 and 1659 cm are not as prominent in vivo as they 
are in vitro. However, the 1659 cm amide peak appears to 
be diagnostically relevant. The nucleic acid peak at 1325 
cm' is much more intense in vivo. All other Raman peaks 
appear Similar in Vivo as well as in vitro. 
The unpaired ratio algorithms developed in Vitro 
(Appendix I) correctly classify the one diseased sample in 
patient 2. It is interesting to note that this lesion was 
incorrectly identified as a human papilloma viral infection 
under colposcopic impression by the participating practitio 
ner. This indicates in Vivo Raman spectra has the potential 
to provide the diagnostic information necessary to distin 
guish between SILS and non-SILS. 
In Vivo tissue Raman spectra measured here still display 
an overlap of Silica and tissue Raman Signal, indicated by the 
intense Raman peaks at 626 and 818 cm. It is hypothesized 
that although Some contribution to this interfering Signal 
may arise from the fibers and optics used in the probe, the 
primary Source of Signal is the quartz, Shield used as a barrier 
between the probe and the Sample. A thinner quartz shield 
may reduce this background Signal but will not eliminate it. 
Most known materials that could potentially be used as a 
window, Such as Sapphire and transparent Teflon, have a 
distinct Raman signal that would be detected by the probe. 
However, it should be noted that the Raman peaks of these 
materials are much narrower than that of quartz or tissue, 
which may allow its Subtraction without loSS of tissue peaks. 
Hence these materials may provide an alternative to quartz 
as a probe window. A probe built with a removable window 
would allow several different materials to be tested, in 
accordance with the teachings provided herein, before mak 
ing an appropriate Selection. 
A possible improvement in the clinical Raman System is 
the use of a higher power laser. Although the use of a higher 
power laser was discarded earlier, the laser power at the tip 
of the probe in this study was 15 mW with a spot size of 
about 900 mm, resulting in an increase in calculated tem 
perature of only 1.5 C. after 5 minutes. Given the spot size 
at the Sample from the Raman probe, a laser power of up to 
80 mW could be used with a corresponding rise in cervical 
tissue temperature of 6 C. A higher power laser in con 
junction with the CCD camera could improve the integration 
time to about 15 seconds (Table 1, column 7). 
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APPENDIXI: PRINCIPAL COMPONENTS 
Algorithm for entire spectrum: 
Spectra # Sample Sample Type PC2 PC3 PC6 PC10 PC11 PC22 
1. 205 Norma 1543567 6.3483O7 -11.5265 -3.85568 -0.35106 2O74359 
2 2O6 Norma 0.675776 7.682844 -3.1951 -1.88044 2.75.8224 1.411211 
3 208 Norma 3.023087 8.267263 4.48342 -2.66354 1.1581 1.35OO89 
4 210 Norma 2.7953O2 7.981375 -8.48441 -4.54498 O.O996.19 2.612589 
5 211 Norma 0.584.463 4.663981 -7.7627 -3.6O148 O411765 2.108621 
6 212 Norma 1145271 4.26O482 -6.33389 -198227 O.475544 0.919255 
7 214 Norma 1.596303 4.153986 -6.00904 -2.25171 O.O54386 1.753455 
8 216 Norma 10.241.84 2.7241.57 -8.21057 -1.598 O.794613 -OOOO61 
9 218 Norma 3.184082 9.355728 -8.06321 -1.25937 -0.40054 1947161 
1O 220 Norma -5.27235 7.425923 -9.O2191 -0.50585 -O.95993 2.127007 
11 224 Norma 3.014144 6.76035 -5.O1533 -2.0569 -1.5O138 1.871378 
12 226 Norma O.92O394 10.87519 4.232368 -3.38003 O.24081 2.185378 
13 228 Norma 1253544 1864631 -8.27384 -2.425.45 O.O48752 1.348167 
14 230 Norma 2.832O68 5.122482 -2.88.442 -0.8595 -018846 1.910948 
15 234 Norma 4.334318 4948299 -9.9853 -3.10534 5.58.3419 1.5OO318 
16 235 Norma 1.524456 -1.26834 -3.73109 -7.37921 -0.67991 2.57 2718 
17 236 Norma -1.1622 4.14058 -7.10158 -5.46803 1.238561 3.035817 
18 238 Norma 4.743856 -0.26435 -6.10788 -3.291O7 1.105041 2.248523 
19 240 Norma 1776385 -2.27109 -4.4548 O.O72194 -0.44392 3.32O742 
2O 217 Metaplasia 1.752317 5.937658 -5.67794 - 1.90O16 O.O85876 O.403281 
21 219 Metaplasia 3.278303 3.265713 -6.14614 -5.1945.4 3.596982 2.192891 
22 221 Inflammation 4.702379 9.837OO1 - 12.0999 -2.75127 -O.9469 1.738.687 
23 222 Inflammation 3.296,747 8.903145 -2.01524 -6.28O15 -1.65013 1.3O3856 
24 223 Inflammation 6.006808 9.88O243 - 7.69385 -0.1685 3.816562 3.699.493 
25 232 Inflammation O569056 4.714893 -7.50604 -6.2.1167 3.826786 O.6O7226 
26 207 Low Grade SIL O561945 5.6O2499 -4.57135 -2.37876 1.373767 O.89OO93 
27 227 Low Grade SIL -080711 5.6532O7 -5.48179 -1.7OO89 2.738.444 1.496372 




APPENDIXI: PRINCIPAL COMPONENTS 
Algorithm for entire spectrum: 
Spectra # Sample Sample Type PC2 PC3 PC6 
29 239 Low Grade SIL -2.25774 -O.10565 -6.798.54 
3O 209 High Grade SIL 2.53.3221 6.647742 -5.789.31 
31 213 High Grade SIL -O.O895 2.906415 -6.OO665 
32 215 High Grade SIL -0.7773 3.910833 -4.O2586 
33 225 High Grade SIL 2.27 2768 1.O92567 -4.6O775 
34 229 High Grade SIL -22.5061 5.707699 -8.81068 
35 231 High Grade SIL O.676066 1891O38 -2.5O145 
36 233 High Grade SIL -0.45883 -1.0537 -3.62572 
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Algorithm for eight intensities: 
Spectra # Sample # Sample Type PC1 PC2 
1. 205 Norma 1.1458848 -3.1255965 2O 
2 2O6 Norma 1.1901.133 -2.5139951 
3 208 Norma 1834,169 -3.0472687 
4 210 Norma 1.9385339 -3.0518833 
5 211 Norma 1.2691274 -2.34.43378 
6 212 Norma 1.3146177 -1982O707 
7 214 Norma 1.2224279 -2.204537 25 
8 216 Norma 6.86261.89 -2.79922.57 
9 218 Norma 3.2312321 -4.2633651 
1O 220 Norma 5.0182456 -1.6O72238 
11 224 Norma 4.96O3838 -2.0805216 
12 226 Norma 6.2O36942 -2.51O9298 
13 228 Norma 9.211.4828 -2.983O391 3O 
14 230 Norma 5.2514816 -2.8O88963 
15 234 Norma 5.9115984 -2.78O9312 
16 235 Norma 4.1752O79 -1.3949086 
17 236 Norma 4.3566OO1 -0.048286O78 
18 238 Norma 6.69.3896 -16661062 
19 240 Norma 4.9669.454 -1.440043 35 
2O 217 Metaplasia 4.1.113339 -1.4176762 
21 219 Metaplasia 5.3999799 -1285,7701 
22 221 Inflammation 5.7796724 -3.763.3856 
23 222 Inflammation 6.3565578 -2.4393958 
24 223 Inflammation 5.7032673 -2.8104215 
25 232 Inflammation 3.9806831 -2.5245282 40 
26 207 Low Grade SIL 1.4079334 -2.40O3275 
27 227 Low Grade SIL 3.5186656 -1.4919014 
28 237 Low Grade SIL 4.7394294 -0.33047979 
29 239 Low Grade SIL 5.2064229 -0.94.494107 
3O 209 High Grade SIL 2.3771245 -2.6865,663 
31 213 High Grade SIL 0.70798.509 -1.3977.078 
32 215 High Grade SIL 3.0091378 -0.80670927 45 
33 225 High Grade SIL 4.3683959 -0.78866125 
34 229 High Grade SIL 4.0888702 O.794.44495 
35 231 High Grade SIL 3.1164238 -0.86678825 
36 233 High Grade SIL 3.8430913 -0.36249117 
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What is claimed is: 
1. An optical probe for in Vivo examination comprising: 
(a) a probe body having an optical opening at one end 
thereof; 
(b) an excitation leg disposed in the probe body, said 
excitation leg having an optical axis, 
(c) a filter for eliminating all but a Selected excitation 
wavelength, disposed in the excitation leg, in operable 
relation to the optical axis of Said excitation leg, 
(d) a collection leg disposed in the probe body, said 
collection leg having an optical axis, 
(e) a mirror in operable relation to said optical axis of said 
excitation leg. 
2. The optical probe of claim 1, wherein Said excitation 
and collection legs are separate. 
3. The optical probe of claim 1, wherein said excitation 
leg is comprised of optical excitation fibers and Said collec 





PC10 PC11 PC22 
-0.49424 -133124 2.20795 
-2.68879 1717242 2.4755.75 
-2.58069 O.O35438 O.931105 
O626846 3.715693 2.181627 
- 4.32622 1.494353 O.333735 
-3.32392 1213121 1.2598.96 
-2.5.4445 3.625.361 2.3936.29 
0.717738 1.235546 O.2O2693 
4. The optical probe of claim 3, wherein said excitation 
leg and Said collection leg are disposed longitudinally in Said 
probe body. 
5. The optical probe of claim 4, wherein said mirror 
establishes an optical path from Said optical axis of Said 
excitation leg to Said optical opening. 
6. The optical probe of claim 1, wherein said excitation 
leg comprises a focusing lens. 
7. The optical probe of claim 6, wherein said filter is 
disposed in operable relation to Said focusing lens. 
8. The optical probe of claim 1, wherein said collection 
leg comprises a focusing lens. 
9. The optical probe of claim 8, wherein said collection 
leg comprises a filter in operable relation to Said focusing 
lens. 
10. The optical probe of claim 9, further comprising a 
collimating lens, in operable relation to Said optical opening. 
11. The optical probe of claim 10, wherein said collimat 
ing lens is about 8 mm in diameter and blockS light having 
an OD of greater than about 6. 
12. The optical probe of claim 7, wherein said filter is an 
interference filter. 
13. The optical probe of claim 12, wherein said interfer 
ence filter is a bandpass filter. 
14. The optical probe of claim 13, wherein said bandpass 
filter is about 3–4 mm in diameter and blocks light with an 
OD of greater than about 5. 
15. The optical probe of claim 9, wherein said filter is a 
longpass filter. 
16. The optical probe of claim 9, wherein said filter is a 
notch filter. 
17. The optical probe of claim 16, wherein said notch 
filter is a holographic notch filter. 
18. The optical probe of claim 17, wherein said holo 
graphic notch filter is about 8 mm in diameter. 
19. An optical probe for in Vivo examination comprising: 
(a) a probe body, wherein the interior of Said probe is 
anodized; 
(b) an optical opening at one end of Said probe body; 
(c) an excitation leg disposed in the probe body, said 
excitation leg having an optical axis, 
(d) a collection leg disposed in the probe body, said 
collection leg having an optical axis, and 
(e) a mirror in operable relation to Said optical axis of Said 
excitation leg. 
20. The optical probe of claim 1, further comprising a 
Shield covering Said optical opening. 
21. The optical probe of claim 20, wherein said shield is 
comprised of quartz. 
22. The optical probe of claim 20, wherein said shield is 
comprised of Sapphire. 
23. The optical probe of claim 20, wherein said shield is 
comprised of transparent Teflon. 
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24. The optical probe of claim 1, wherein the diameter of 
said probe is less than 20 mm. 
25. The optical probe of claim 3, wherein the number of 
said collection fibers is 50. 
26. The optical probe of claim 3, wherein the size of said 
collection fibers is 100 lum. 
27. An optical probe for in Vivo examination comprising: 
(a) a probe body having an optical opening at one end 
thereof; 
(b) an excitation leg disposed in the probe body, said 
excitation leg having an optical axis, 
(c) a collection leg disposed in the probe body, said 
collection leg having an optical axis, and 
(e) a mirror in operable relation to said optical axis of said 
excitation leg, wherein Said mirror is comprised of a 
polished gold wire. 
28. The optical probe of claim 27, wherein said polishing 
is at a specific angle greater than the critical angle of quartz. 
29. The optical probe of claim 1, wherein said mirror is a 
parabolic mirror. 
30. The optical probe of claim 1, wherein said probe body 
is comprised of carbonized epoxy. 
31. An optical probe for in Vivo examination comprising: 
(a) a probe body, wherein said probe body is comprised of 
aluminum; 
(b) an optical opening at one end of Said probe body; 
(c) an excitation leg disposed in the probe body, said 
excitation leg having an optical axis, 
(d) a collection leg disposed in the probe body, said 
collection leg having an optical axis: and 
(e) a mirror in operable relation to said optical axis of said 
excitation leg. 
32. The optical probe of claim 1, wherein Said probe body 
is encased in heat-shrink tubing. 
33. The optical probe of claim 32, wherein the probe 
optical window comprises a Shield. 
34. An optical probe for in Vivo examination comprising: 
an elongated probe body having an optical window at one 
end thereof; 
an optical fiber disposed Substantially longitudinally in 
the probe body, the optical fiber having first and Second 
ends, 
an electromagnetic Source coupler mounted on the probe 
body and coupled to the first end of the optical fiber; 
a first focusing lens disposed in the probe body and having 
an optical axis Substantially normal to the Second end 
of the optical fiber; 
an interference filter disposed in the probe body on the 
optical axis of the first focusing lens, 
a deflecting mirror disposed in the probe body on the 
optical axis of the first focusing lens, the interference 
filter being disposed between the first focusing lens and 
the deflecting mirror; 
an optical fiber bundle disposed Substantially longitudi 
nally in the probe body, the optical fiber bundle having 
first and Second ends, 
an electromagnetic receiver coupler mounted on the probe 
body, the electromagnetic receiver coupler being 
coupled to the first end of the optical fiber bundle; 
a collimating lens disposed in the probe body and having 
an optical axis Substantially normal to the Second end 
of the optical fiber bundle; 
a holographic filter disposed in the probe body on the 
optical axis of the collimating lens and Substantially 
normal thereto, and 
a Second focusing lens disposed in the probe body and 











Second end of the optical fiber bundle, the holographic 
filter being disposed between the collimating lens and 
the Second focusing lens, 
wherein the deflection mirror is angled with respect to the 
optical axis of the first focusing lens to establish an optical 
path from the optical axis of the first focusing lens that 
intersects with the optical axis of the Second focusing lens in 
a region proximate to and outside of the probe optical 
window. 
35. An apparatus for measuring Raman spectra in vivo 
comprising: 
a probe according to claim 1, 
an electromagnetic radiation generator, 
a Raman spectrum detector; and 
a means for analyzing Said spectra in relation to Said 
electromagnetic radiation. 
36. The apparatus of claim 35, wherein said generator is 
a laser. 
37. A method for collecting optical data from a Sample site 
in Vivo comprising: 
generating excitation electromagnetic energy; 
conducting the excitation energy longitudinally through a 
probe; 
concentrating the excitation energy during the excitation 
energy conducting Step; 
filtering the excitation energy during the excitation energy 
conducting Step to eliminate all but a predetermined 
excitation wavelength from the excitation energy; 
deflecting the excitation energy following the concentra 
tion and filtering Steps onto the Sample site; 
conducting emission radiation resulting from the deflect 
ing Step longitudinally through the probe, 
expanding the emission radiation during the emission 
radiation conducting Step; 
interference filtering the emission radiation during the 
emission radiation conducting Step and after the 
expanding Step to eliminate the excitation wavelength 
from the emission radiation; 
concentrating the emission radiation during the emission 
radiation conducting Step and following the interfer 
ence filtering Step; and 
collecting the emission radiation following the concen 
trating Step. 
38. The method of claim 37, wherein the probe comprises 
a window at an end thereof, the window having known 
fluorescence and Raman Signatures, and further comprising 
the Steps of bringing the window into proximity with the 
tissue site during the collection Step, and removing the 
known fluorescence and Raman Signatures from the col 
lected emission radiation. 
39. An optical probe for in Vivo examination comprising: 
(a) a probe body having an optical opening at one end 
thereof, 
(b) an excitation leg disposed in the probe body, said 
excitation leg having an optical axis, and being trans 
parent to a Selected excitation wavelength, 
(c) a collection leg disposed in the probe body, said 
collection leg having an optical axis, 
(d) a filter for filtering said selected excitation 
wavelength, disposed in the collection leg, in operable 
relation to the optical axis of Said collection leg; and 
(e) a mirror in operable relation to Said optical axis of Said 
excitation leg. 
